. "MHC class I status of tumours and design of immunotherapeutic strategies."@en . "Attention should be paid to the MHC class I status of neoplasms during the design of immunotherapy protocols. For therapy of MHC class I deficient tumours, cytokines such as IFN gamma, IL-12, IL-2, GM-CSF, either exogenous or produced by gene-modified vaccines, should be considered. The therapeutic role of the induction of MHC class I expression by demethylation and acetylation agents should also be investigated."@en . . . "2-3" . . . . "615368" . . . "1"^^ . "Immunology Letters" . "P(GA301/01/0985), P(IAA5052203), P(NC6957), P(NC7148), P(NC7552), Z(AV0Z5052915)" . "MHC; beta2-mikroglobulin; immunotherapeutic strategies"@en . "0"^^ . . "2"^^ . "0"^^ . . . "90" . "MHC class I status of tumours and design of immunotherapeutic strategies." . "Attention should be paid to the MHC class I status of neoplasms during the design of immunotherapy protocols. For therapy of MHC class I deficient tumours, cytokines such as IFN gamma, IL-12, IL-2, GM-CSF, either exogenous or produced by gene-modified vaccines, should be considered. The therapeutic role of the induction of MHC class I expression by demethylation and acetylation agents should also be investigated." . . "2"^^ . . . "MHC class I status of tumours and design of immunotherapeutic strategies." . "177;178" . "NL - Nizozemsko" . "Buben\u00EDk, Jan" . "RIV/68378050:_____/03:23033192" . . "MHC class I status of tumours and design of immunotherapeutic strategies."@en . "0165-2478" . . . "Vonka, V." . . . . "RIV/68378050:_____/03:23033192!RIV/2004/GA0/A23004/N" . "[5015A8E6BFBE]" . .